Fresh analysis suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt conventional lifestyle plans.
Findings released in a leading health publication points out that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals using such drugs must be informed of the danger of fast weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment weight within about one and a half years.
Weighing Approaches
The analysis, which examined 37 of trials involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
The team point out that people who shed pounds through dieting generally see a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Nutrition scientists suggest the way of the injections accounts for the accelerated rebound.
The injections imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement means hunger is uncontrolled, making overeating much more probable."
An Ongoing Issue?
The NHS advise the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals say that, given the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is echoed by drug manufacturers, who say that the findings "underscore the persistent nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Testimonies
People who have discontinued the jabs report a intense return of appetite.
"It was like something activating and I was suddenly extremely hungry," described one woman.
The struggle is worsened if users have not established permanent dietary or behavioural modifications during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
Ultimately, researchers caution that while these medications are effective agents for shedding pounds, they are not a magic solution and long-term success likely depends on combined lifestyle management.
